AUPH (Aurinia Pharmaceuticals) LT-Debt-to-Total-Asset: 0.07 (As of Mar. 2026)

What is Aurinia Pharmaceuticals LT-Debt-to-Total-Asset?

Aurinia Pharmaceuticals AUPH -1.14% 81 LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.00 (Modestly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aurinia Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.07.

Aurinia Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.12) to Mar. 2026 (0.07). It may suggest that Aurinia Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Aurinia Pharmaceuticals (NAS:AUPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aurinia Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Aurinia Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals LT-Debt-to-Total-Asset Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.15

0.12

0.08

Aurinia Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.13	0.12	0.08	0.07

81GF Score

Aurinia Pharmaceuticals Inc AUPH

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aurinia Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Aurinia Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	57.222	/	751.587
	=	0.08

Aurinia Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	50.499	/	723.997
	=	0.07

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.07 mean?

Aurinia Pharmaceuticals (AUPH) has a LT-Debt-to-Total-Asset of 0.07 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aurinia Pharmaceuticals and its competitors.

Is Aurinia Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Aurinia Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.07. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aurinia Pharmaceuticals' LT-Debt-to-Total-Asset compare to KOD and ABCL?

Aurinia Pharmaceuticals' LT-Debt-to-Total-Asset of 0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aurinia Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.00, compared to a current price of $15.61 — trading 11.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.07. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.61 is trading 11.5% above its estimated GF Value™ of $14.00. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

LT-Debt-to-Total-Asset: 0.07
GF Value™: $14.00 vs. price of $15.61 (11.5% above fair value)
GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies KOD ABCL AGIO IMNM OCUL NKTR PVLA GENB SLBT NTLA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IKAP:Germany

Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

81GF Score

Get the complete analysis for AUPH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.61

Price

$14.00

GF Value

View AUPH Analysis

See LT-Debt-to-Total-Asset data for all stocks →